RBC Capital analyst Brian Abrahams upgrades BioCryst Pharma (NASDAQ:BCRX) from Sector Perform to Outperform and raises the price target from $9 to $10.
RBC Capital Upgrades BioCryst Pharma to Outperform, Raises Price Target to $10
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.